Now showing items 1-5 of 5

    • Copy Number Profiling of Brazilian Astrocytomas. 

      Bidinotto, LT; Torrieri, R; Mackay, A; Almeida, GC; Viana-Pereira, M; Cruvinel-Carloni, A; Spina, ML; Campanella, NC; Pereira de Menezes, W; Clara, CA; Becker, AP; Jones, C; Reis, RM (2016-07-07)
      Copy number alterations (CNA) are one of the driving mechanisms of glioma tumorigenesis, and are currently used as important biomarkers in the routine setting. Therefore, we performed CNA profiling of 65 astrocytomas of ...
    • Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives. 

      Szopa, W; Burley, TA; Kramer-Marek, G; Kaspera, W (2017-01)
      Glioblastoma (GBM) is a primary neuroepithelial tumor of the central nervous system, characterized by an extremely aggressive clinical phenotype. Patients with GBM have a poor prognosis and only 3-5% of them survive for ...
    • Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci. 

      Labreche, K; Kinnersley, B; Berzero, G; Di Stefano, AL; Rahimian, A; Detrait, I; Marie, Y; Grenier-Boley, B; Hoang-Xuan, K; Delattre, J-Y; Idbaih, A; Houlston, RS; Sanson, M (2018-05)
      Recent genome-wide association studies of glioma have led to the discovery of single nucleotide polymorphisms (SNPs) at 25 loci influencing risk. Gliomas are heterogeneous, hence to investigate the relationship between ...
    • MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. 

      Lampis, A; Carotenuto, P; Vlachogiannis, G; Cascione, L; Hedayat, S; Burke, R; Clarke, P; Bosma, E; Simbolo, M; Scarpa, A; Yu, S; Cole, R; Smyth, E; Mateos, JF; Begum, R; Hezelova, B; Eltahir, Z; Wotherspoon, A; Fotiadis, N; Bali, MA; Nepal, C; Khan, K; Stubbs, M; Hahne, JC; Gasparini, P; Guzzardo, V; Croce, CM; Eccles, S; Fassan, M; Cunningham, D; Andersen, JB; Workman, P; Valeri, N; Braconi, C (2018-03)
      BACKGROUND & AIMS:Cholangiocarcinomas (CCA) are resistant to chemotherapy, so new therapeutic agents are needed. We performed a screen to identify small-molecule compounds that are active against CCAs. Levels of microRNA ...
    • Novel therapeutic approaches in chondrosarcoma. 

      Polychronidou, G; Karavasilis, V; Pollack, SM; Huang, PH; Lee, A; Jones, RL (2017-03)
      Chondrosarcoma is a malignant tumor of bones, characterized by the production of cartilage matrix. Due to lack of effective treatment for advanced disease, the clinical management of chondrosarcomas is exceptionally ...